Literature DB >> 11468882

Evaluation of vancomycin use in a large university-affiliated hospital in eastern France in 1999.

N Floret1, M Thouverez, B Thalamy, J M Estavoyer, D Talon.   

Abstract

OBJECTIVE: In 1999, we conducted a retrospective drug utilization review to determine the volume and pattern of vancomycin use in a university-affiliated hospital in eastern France.
METHODS: Total vancomycin use was determined and expressed as vancomycin courses per 100 admitted patients and defined daily doses (DDD) of vancomycin per 100 patient-days. The indication for vancomycin use was classified as appropriate or inappropriate according to the guidelines issues by the HICPAC.
RESULTS: A total of 311 vancomycin courses were given, as 2098 DDD, giving crude incidences of 1.17 courses per 100 admitted patients and of 1.19 defined daily doses per 100 patient-days. The frequency of appropriate courses was 66.7%. Of the 63 inappropriate courses of vancomycin, 39.7% and 28.6% were empiric therapy for nosocomial and community-acquired infections, respectively, 20.6% and 6.3% were specific therapy for nosocomial and community-acquired infections, respectively, and 4.7% were prophylactic.
CONCLUSIONS: This study shows that vancomycin use in our hospital resulted in a lower selection pressure than has been reported for US university-affiliated hospitals and that comprehensive programs to improve use of vancomycin are needed in our institution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468882     DOI: 10.1023/a:1011269131048

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  3 in total

1.  Effect of utilization policies for fluoroquinolones: a pilot study in nova scotia hospitals.

Authors:  Andrea J Kent; Ingrid S Sketris; B Lynn Johnston; Ryan B Sommers
Journal:  Can J Hosp Pharm       Date:  2009-01

2.  Evaluation of vancomycin use in university-affiliated hospitals in Southern Khorasan Province (East Iran) based on HICPAC guidelines.

Authors:  Motahare Mahi-Birjand; Masood Ziaee; Bita Bijari; Reza Khalvati; Mohammad Reza Abedini; Hasan Golboei Mousavi; Arash Ziaee
Journal:  Drug Healthc Patient Saf       Date:  2019-04-08

3.  Antimicrobial resistance rates in gram-positive bacteria do not drive glycopeptides use.

Authors:  Beryl Primrose Gladstone; Andrea Cona; Parichehr Shamsrizi; Tuba Vilken; Winfred V Kern; Nisar Malek; Evelina Tacconelli
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.